Navigation Links
New Pharmaxis Board Appointment
Date:4/6/2009

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors.

Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. HSMR Advisors has held a position on the Pharmaxis share register since 2005.

During his career Mr van den Broek has worked on both the buy and sell side of the funds management industry holding senior positions at Cooper Hill Partners, Hambrecht & Quist (H&Q), Merrill Lynch and Oppenheimer & Co.

"Richard has been an engaged investor for a number of years and has great insight into the life science industry and the U.S. capital markets," said Pharmaxis Chief Executive Officer, Dr Alan Robertson. "Our shareholders will benefit from his skills and experience."

In accepting the board position Mr van den Broek said: "Pharmaxis holds enormous promise and I look forward to being part of an exciting company at a key point in its development as a global provider of innovative medicines.

I am very much looking forward to working with the Pharmaxis Board."

Mr van den Broek is a Chartered Financial Analyst, and is a graduate of Harvard University.

    For information on all Pharmaxis Board members, go to:
   http://www.pharmaxis.com.au/about-us/our-people/our-people_home.cfm

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson -- Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:
     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Investor Conference Call
2. Pharmaxis Appoints French Distributor for Aridol(TM)
3. Pharmaxis Builds Senior Management Team
4. Pharmaxis Investor Conference Call
5. Pharmaxis Aridol Approved for Sale in Switzerland
6. Pharmaxis Investor Conference Call
7. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
8. New Pharmaxis Board Appointment
9. Pharmaxis Aridol Authorised for Sale in Germany
10. Pharmaxis First Steps into China
11. Pharmaxis to Apply to Market Bronchitol in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem Cells ... with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and other ... including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, ...
(Date:2/10/2016)...  The Maryland House of Delegates and House Speaker ... of Maryland School of Medicine Dean E. Albert ... Medical System President and CEO Robert Chrencik , ... honor given to the public by the leader of ... and Mr. Chrencik for their contributions to our ...
(Date:2/10/2016)...  IsoRay, Inc. (NYSE MKT: ISR), a medical technology ... applications for the treatment of prostate, brain, lung, head ... results for the second quarter and six months of ... --> --> Revenue was ... which ended December 31, 2015, a 12% increase compared ...
Breaking Biology Technology:
(Date:2/4/2016)... The field of Human Microbiome research ... popular hubs of the biotechnology industry. While the ... of human microbiota, have garnered a lot of ... space has literally exploded in terms of both ... focuses on biomedical aspects of research, development, and ...
(Date:2/3/2016)... 2016 http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ... "Emotion Detection and Recognition Market by ... Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020" report ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition of ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
Breaking Biology News(10 mins):